July 2021 and held senior global roles at Shire plc, Cubist Pharmaceuticals, Inc., Blueprint Medicines, Corp. and Genzyme Corporation. Ms. Fisher holds a B.S. in Biochemistry from the University of Bath, as well as an M.B.A. from Henley Management College in the United Kingdom.
We believe that Ms. Fisher is qualified to serve on our Board of Directors due to her educational background and experience as a senior executive of biotechnology and pharmaceutical companies.
Directors Continuing in Office Until the 20222025 Annual Meeting of Stockholders
Andrew Allen, M.D., Ph.D. has served as a member of our Board of Directors since August 2015. Dr. Allen co-founded Gritstone Oncology, Inc. and has served as our President and Chief Executive Officer and a member of our board of directors since SeptemberAugust 2015. Prior to Gritstone, in April 2009, Dr. Allen co-founded Clovis Oncology, Inc., a public pharmaceutical development company, and served as its executive vice presidentExecutive Vice President of clinicalClinical and preclinical developmentPreclinical Development and chief medical officerChief Medical Officer from April 2009 to July 2015. Prior to that role, he was chief medical officerChief Medical Officer at Pharmion Corporation, a biotechnology company that was acquired by Celgene Corporation, from 2006 to 2008. Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation, a biotechnology company that was acquired by Novartis International AG, and Abbott Laboratories, a public medical devices and healthcare company, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the boardboards of directors of Epizyme, Inc., a publicly traded biopharmaceutical company, Sierra Oncology, Inc., a publicly traded biopharmaceutical company, TCR2 Therapeutics Inc, a publicly tradedpublic biopharmaceutical company, and Revitope Inc., a privately-heldprivate biotechnology company, and Verge Genomics, Inc., a private biotechnology company. Dr. Allen previously served on the boardboards of directors of Sierra Oncology, Inc., a public biopharmaceutical company, from October 2017 until its acquisition by GSK in April 2022, Cell Design Labs, Inc., a private biotechnology company, from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017.2017, and Epizyme from June 2014 until November 2021. Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London.
We believe that Dr. Allen is qualified to serve on our boardBoard of directorsDirectors due to his educational experience and his experience as a senior executive of public and private biotechnology and pharmaceutical companies, including his service as our chief executive officer.Chief Executive Officer and President.
Judith LiDr. Naiyer A. Rizvi is a co-founder and has served as a member of our Board of Directors since June 2021. Dr. Rizvi is Chief Medical Officer at Synthekine Inc., a private, engineered and synthetic cytokine therapeutics company. Until May 2021, he was the Price Family Professor of Medicine, Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy at Columbia University Medical Center. Dr. Rizvi served on the board of directors since September 2017. Ms. Li has served asof ARMO BioSciences Inc., a partnerpublic biotechnology company until its acquisition by Eli Lilly and Co., from June 2017 to May 2018. From 1990 to 1995, Dr. Rizvi was an attending physician in thoracic oncology and early drug development at Lilly Asia Ventures (“LAV”), which is basedMemorial Sloan Kettering Cancer Center, where his translational research focused on immune-checkpoint blockade drug development. He received an M.D. at the University of Manitoba in Hong KongWinnipeg, Canada, and Shanghai and focuses on early and growth stage investments across biopharmaceuticals,completed a fellowship in medical devices, and diagnostics, both domestically and cross-border, since 2013. Judith is currently a board member of various LAV portfolio companies, including Tmunity Therapeutics, Scineuro Pharmaceuticals, and Fortis; as well as a former board member of EScape Bio and Veritas Genetics Inc. She has also previously served as a board director on public companies Inhibrx and Nextcure, Inc., and Crown BioScience Inc. Previously, Ms. Li served as a senior business analystoncology at McKinsey & Company, worked in hospital administration at Partners Healthcare, and co-founded an interventional nephrology medical device venture. Judith holds a B.A. in biology from Beth Israel Hospital/Harvard and an M.B.A. from Harvard BusinessMedical School.
We believe that Ms. LiDr. Rizvi is qualified to serve on our board of directors due to her experience as a board member of biotechnology and pharmaceutical companies, and her experience as an investor in new life sciences companies.
Directors Continuing in Office Until the 2023 Annual Meeting of Stockholders
Richard Heyman, Ph.D. has served as a member of our board of directors since November 2015. Dr. Heyman is executive chairman and co-founder of Metacrine, Inc., a biotechnology company developing new therapeutics for the treatment of liver and gastrointestinal diseases. He also is the co-founder and chairman of ORIC Pharmaceuticals, which is developing drugs to overcome resistance in cancer. Previously, Dr. Heyman served as president and chief executive officer of Seragon Pharmaceuticals Inc. (“Seragon”), a privately-held biotechnology company, which was acquired by Genentech in 2014. Prior to Seragon, he co-founded and served as president and chief executive officer of Aragon Pharmaceuticals, Inc. until it was purchased by Johnson & Johnson in 2013. He has been involved in the discovery and development of multiple therapeutic agents approved by the FDA, including the recently approved prostate cancer drug, Erleada. Dr. Heyman is a venture partner for Arch Ventures and serves on the Board of Directors for Ymanity Therapeutics and Vividion Therapeutics. He is Vice Chair of the Board of Trustees at the Salk Institute, on the Board Foundation for the American Association for Cancer Research and on the executive committee at the University of California at San Diego Moores Cancer Center. He has won numerous awards, including Ernst and Young San Diego Regional Entrepreneur of the Year and the Endocrine Society Outstanding Innovation Award. Dr. Heyman received a B.S. in chemistry from the University of Connecticut and a Ph.D. in pharmacology from the University of Minnesota. He was an NIH post-doctoral fellow and staff scientist at the Salk Institute. We believe that Dr. Heyman is qualified to serve on our board of directors due to his educational background and his experience as a board member and senior executive of biotechnology and pharmaceutical companies.
Nicholas Simon has served as a member of our board of directors since September 2015. Mr. Simon is a Senior Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus Ventures, LLC (“Clarus”) in December of 2018. Prior to joining Blackstone, Mr. Simon was co-founder and Managing Director of Clarus, a venture capital firm focused on life sciences companies, since the firm’s inception in 2005. Prior to Clarus, Mr. Simon was a general partner at MPM Capital, Inc., a healthcare venture